165 related articles for article (PubMed ID: 31923416)
1. Quantitative analysis of metabolites in glucose metabolism in the aqueous humor of patients with central retinal vein occlusion.
Wei P; He M; Teng H; Han G
Exp Eye Res; 2020 Feb; 191():107919. PubMed ID: 31923416
[TBL] [Abstract][Full Text] [Related]
2. Higher Aqueous Levels of Resistin and Lipocalin-2 Indicated Worse Visual Improvement following anti-VEGF Therapy in Patients with Retinal Vein Occlusion.
Luo Y; Wan J; Luo C; Liu H; Zhou Y; Chen J; Duan Y; Ning X; Zhou Z; Wang K; Li J; Xu H; Chen Z
Curr Eye Res; 2021 Jun; 46(6):845-854. PubMed ID: 33103481
[TBL] [Abstract][Full Text] [Related]
3. Aqueous semaphorin 3A level correlates with retinal macular oedema and ganglion cell degeneration in patients with retinal vein occlusion.
Guo S; Ren J; Li Z; Fan X; Qin L; Li J
Acta Ophthalmol; 2019 May; 97(3):273-278. PubMed ID: 30803163
[TBL] [Abstract][Full Text] [Related]
4. Glucose Metabolic Characterization of Human Aqueous Humor in Relation to Wet Age-Related Macular Degeneration.
Han G; Wei P; He M; Teng H
Invest Ophthalmol Vis Sci; 2020 Mar; 61(3):49. PubMed ID: 32232346
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion.
Rezar-Dreindl S; Eibenberger K; Pollreisz A; Bühl W; Georgopoulos M; Krall C; Dunavölgyi R; Weigert G; Kroh ME; Schmidt-Erfurth U; Sacu S
Acta Ophthalmol; 2017 Mar; 95(2):e119-e127. PubMed ID: 27417275
[TBL] [Abstract][Full Text] [Related]
6. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.
Funk M; Kriechbaum K; Prager F; Benesch T; Georgopoulos M; Zlabinger GJ; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1025-32. PubMed ID: 19060280
[TBL] [Abstract][Full Text] [Related]
7. Role of Cytokines in Ranibizumab Therapy for Macular Edema in Patients with Central Retinal Vein Occlusion.
Matsushima R; Noma H; Yasuda K; Goto H; Shimura M
J Ocul Pharmacol Ther; 2019 Sep; 35(7):407-412. PubMed ID: 31373873
[No Abstract] [Full Text] [Related]
8. Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in central retinal vein occlusion with macular edema.
Noma H; Mimura T; Yasuda K; Shimura M
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1122-8. PubMed ID: 25634982
[TBL] [Abstract][Full Text] [Related]
9. Higher aqueous levels of matrix metalloproteinases indicated visual impairment in patients with retina vein occlusion after anti-VEGF therapy.
Luo Y; Wan J; Luo C; Liu H; Zhou Y; Xu H; Chen Z
Br J Ophthalmol; 2021 Jul; 105(7):1029-1034. PubMed ID: 31843793
[TBL] [Abstract][Full Text] [Related]
10. Six-month changes in cytokine levels after intravitreal bevacizumab injection for diabetic macular oedema and macular oedema due to central retinal vein occlusion.
Wen J; Jiang Y; Zheng X; Zhou Y
Br J Ophthalmol; 2015 Oct; 99(10):1334-40. PubMed ID: 25841235
[TBL] [Abstract][Full Text] [Related]
11. POSSIBLE MOLECULAR BASIS OF BEVACIZUMAB THERAPY FOR MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION.
Noma H; Mimura T; Yasuda K; Shimura M
Retina; 2016 Sep; 36(9):1718-25. PubMed ID: 26866529
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
Lim JW
Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
[TBL] [Abstract][Full Text] [Related]
13. Metabolomic analysis of the aqueous humor from patients with central retinal vein occlusion using UHPLC-MS/MS.
Wei P; He M; Teng H; Han G
J Pharm Biomed Anal; 2020 Sep; 188():113448. PubMed ID: 32622112
[TBL] [Abstract][Full Text] [Related]
14. Role of Novel Inflammatory Factors in Central Retinal Vein Occlusion with Macular Edema.
Yasuda K; Noma H; Mimura T; Nonaka R; Sasaki S; Ofusa A; Shimura M
Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38276038
[No Abstract] [Full Text] [Related]
15. Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab.
Brogan K; Precup M; Rodger A; Young D; Gilmour DF
BMC Ophthalmol; 2018 Feb; 18(1):37. PubMed ID: 29426292
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
17. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study.
Georgalas L; Tservakis I; Kiskira EE; Petrou P; Papaconstantinou D; Kanakis M
Cutan Ocul Toxicol; 2019 Dec; 38(4):330-337. PubMed ID: 31060385
[No Abstract] [Full Text] [Related]
19. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
[TBL] [Abstract][Full Text] [Related]
20. Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion.
Sohn HJ; Han DH; Lee DY; Nam DH
Acta Ophthalmol; 2014 May; 92(3):e217-24. PubMed ID: 23889803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
